TRIlogy-3

A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

Near Add Your Location

Sorting 42 by

Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
City of Hope
Long Beach, CA
  • Accepting patients
Texas Oncology
Tyler, TX
  • Accepting patients
Virginia Cancer Specialists
Fairfax, VA
  • Accepting patients
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Texas Oncology
Amarillo Cancer Center
Amarillo, TX
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.